진행성 위암에 대한 5-Fluorouracil, Cisplatin 및 Pirarubicin의 복합항암화학요법
5-Fluorouracil, Cisplatin, and Pirarubicin Combination Chemotherapy for Advanced Gastric Cancer
대한암학회지 1998년 30권 3호 p.475 ~ 481
소속 상세정보
서재홍/Jae Hong Seo
최인근/김석진/김병수/신상원/김열홍/목영재/김종석/김준석/In Keun Choi/Suk Jin Kim/Byung Soo Kim/Sang Won Shin/Yeul Hong Kim/Young Jae Mok/Chong Suk Kim/Jun Suk Kim
KMID : 0360319980300030475
Abstract
결론
진행성 위암환자에서 시행한 5-FU, cisplatin 및 pirarubicin 복합화학요법은 전체반응률이
48.3%(95% 신뢰구간 29.9∼67.1%)이고 중앙생존기간이 7개월로 기존의 다른 복합화학요법
과 의미있는 차이는 보이지 않았고, 모든 환자에서 심독성은 나타나지 않았으나 19명
(51.3%)의 환자에서 Grade 3∼4의 심한 혈액학적 독성을 나타내었고 그 중에서 심한 혈소
판 감소증 또는 다른 독성으로 인하여 11명(29.7%)의 환자에서 용량감량 및 투약일자의 지
연 등이 필요하였고 이러한 점이 전체 반응률 감소에 영향을 주었으리라 생각되었다. 이 복
합화학요법의 임상적 유용성에 대한 평가를 위해서는 추후에 3상 연구가 필요하리라 생각한
다.
Purpose : Gastric cancer is the most common malignancy in Korea. However, standard
systemic combination chemotherapy regimen has not been settled for advanced gastric
cancer. 5-FU, Cisplatin, and Pirarubicin combination chemotherapy regimen has been
tried to evaluate the response rate and toxicity iii advanced gastric cancer patients.
Materials and Methods : Elligibility included biopsy proven inoperable or relapsed
adenocarcinoma of stomach with adequate bone marrow, hepatic, and renal function.
Thirty seven patients with histologically confirmed locally advanced or metastatic gastric
cancer were treated with cisplatin 15 mg/m2 Ⅳ day 1∼5, pirarubicin 60
mg/m2 day 1, 5-fluorouracil 750 mg/mm2 day 1∼5 as a
continuous intravenous infusion.
Results : Twenty nine patients had measurable disease, 5 had received prior
chemotherapy. Performance status was 0∼1 in 24 and 2 in 13. There was 1 complete
response and 13 partial response with an overall response rate of 48.3%(95% confidence
interval 29.9∼67.1%). The median survival is 7 months(95% confidence interval 5.4∼8.6
months) and median response duration is 6 months. 19 patients experienced severe(WHO
grade 3∼4) leucopenia, 7 was thrombocytopenia, 13 was nausea and vomiting during
chemotherapy. 11 patients experienced chemotherapy dose reduction or chemotherapy
time delay due to severe hematologic or non-hematologic toxicities. There was no
clinically recognizable cardiac toxicities.
Conclusion : We experienced 48.3% overall response rate, 7 months median survival,
and 51.3% severe hematologic toxicities with 5-fluorouracil, pirarubicin and cisplatin
combination chemotherapy regimen in advanced or metastatic gastric cancer patients.
키워드
Gastric cancer; Pirarubicin; 5-fluorouracil; Cisplatin;
원문 및 링크아웃 정보
등재저널 정보